[1] PARASKEVAS K I,MIKHAILIDIS D P,VEITH F J.Letter by Paraskevas et al regarding article,"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack:a guideline for healthcare professionals from the American Heart Association/American Stroke Association"[J].Stroke,2011,42(6):e387.
[2] Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324(7329):71-86.
[3] KRASOPOULOS G,BRISTER S J,BEATTIE W S,et al.Aspirin "resistance" and risk of cardiovascular morbidity:systematic review and meta-analysis[J].BMJ,2008,336(7637):195-198.
[4] CUISSET T,FRERE C,QUILICI J,et al.Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting[J].AmHeart J,2009,157(5):889-893.
[5] KASOTAKIS G,PIPINOS I I,LYNCH T G.Current evidence and clinical implications of aspirin resistance[J].J Vasc Surg,2009,50(6):1500-1510.
[6] SCHWARTZ K A,SCHWARTZ D E,BARBER K,et al.Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients[J].J Transl Med,2008,6(1):46.
[7] SCHWARTZ K A,SCHWARTZ D E,GHOSHEH K,et al.Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction[J].Am J Cardiol,2005,95(8):973-975.
[8] BORNSTEIN N M,KAREPOV V G,ARONOVICH B D,et al.Failure of aspirin treatment after stroke[J].Stroke,1994,25(2):275-277.
[9] CHAMORRO A,ESCOLAR G,REVILLA M,et al.Ex vivo response to aspirin differs in stroke patients with single or recurrent events:a pilot study[J].J Neurol Sci,1999,171(2):110-114.
[10] WEBER A A,ZIMMERMANN K C,MEYER-KIRCHRATH J,et al.Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance[J].Lancet,1999,353(9156):900.
[11] GASPARYAN A Y,WATSON T,LIP G Y H.The Role of Aspirin in cardiovascular prevention implications of aspirin resistance[J].J Am Coll Cardiol,2008,51(19):1829-1843.
[12] GUM P A,KOTTKE-MARCHANT K,WELSH P A,et al.A prospective,blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease[J].J Am Coll Cardiol,2003,41(6):961-965.
[13] COHEN H W,CRANDALL J P,HAILPERN S M,et al.Aspirin resistance associated with HbA1c and obesity in diabetic patients[J].J Diabetes Complicat,2008,22(3):224-228.
[14] 柏燕燕,孔玉,高志强,等.合并2型糖尿病脑梗死患者与未合并糖尿病脑梗死患者阿司匹林抵抗的研究[J].现代医学,2014,42(4):435-437.
[15] VENUGOPAL S K,DEVARAJ S,JIALAL I.C-reactive protein decreases prostacyclin release from human aortic endothelial cells[J].Circulation,2003,108(14):1676-1678.
[16] HURLEN M,SELJEFLOT I,ARNESEN H.Increased platelet aggregability during exercise in patients with previous myocardial infarction.Lack of inhibition by aspirin[J].Thromb Res,2000,99(5):487-494.
[17] GULMEZ O,YILDIRIR A,BAL U,et al.Assessment of biochemical aspirin resistance at rest and immediately after exercise testing[J].Blood Coagul Fibrin,2007,18(1):9-13.
[18] XU Z H,JIAO J R,YANG R,et al.Aspirin resistance:clinical significance and genetic polymorphism[J].J Int Med Res,2012,40(1):282-292.
[19] Al-AZZAM S I,ALZOUBI K H,KHABOUR O F,et al.The contribution of platelet glycoproteins (GPIa C807T and GPIba C-5T) and cyclooxygenase 2 (COX-2G-765C) polymorphisms to platelet response in patients treated with aspirin[J].Gene,2013,526(2):118-121.
[20] TAYLOR D W,BARNETT H J M,HAYNES R B,et al.Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:a randomised controlled trial[J].Lancet,1999,353(9171):2179-2184.
[21] ROZALSKI M,BONCLER M,LUZAK B,et al.Genetic factors underlying differential blood platelet sensitivity to inhibitors[J].Pharmacol Rep,2005,57(1):1-13.
[22] JEFFERSON B K,FOSTER J H,MCCARTHY J J,et al.Aspirin resistance and a single gene[J].Am J Cardiol,2005,95(6):805-808.
[23] CATELLA-LAWSON F,REILLY M P,KAPOOR S C,et al.Cyclooxygenase inhibitors and the antiplatelet effects of aspirin[J].New Engl J Med,2001,345(25):1809-1817.
[24] IKEDA T,TANIGUCHI R,WATANABE S,et al.Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan[J].Circ J,2010,74(6):1227-1235.
[25] SCHÄFER A,FRACCAROLLO D,EIGENTHALER M,et al.Rosuvastatin reduces platelet activation in heart failure role of NO bioavailability[J].Arterioscl Throm Vas,2005,25(5):1071-1077.
[26] BAURIEDEL G,SKOWASCH D,SCHNEIDER M,et al.Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel:a pilot study with whole-blood aggregometry[J].Am Heart J,2003,145(2):343-348.
[27] REAVEY-CANTWELL J F,FOX W C,REICHWAGE B D,et al.Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery[J].Neurosurgery,2009,64(5):890-896.
[28] PIGNONE M,ALBERTS M J,COLWELL J A,et al.Aspirin for primary prevention of cardiovascular events in people with diabetes[J].J Am Coll Cardiol,2010,55(25):2878-2886.
[29] SNOEP J D,HOVENS M,EIKENBOOM J C J,et al.Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting:a systematic review and meta-analysis[J].Am Heart J,2007,154(2):221-231.
[30] LEV E I,PATEL R T,MARESH K J,et al.Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary interventionthe role of dual drug resistance[J].J Am Coll Cardiol,2006,47(1):27-33.
[31] JAKUBOWSKI J A,MATSUSHIMA N,ASAI F,et al.A multiple dose study of prasugrel (CS-747),a novel thienopyridine P2Y12 inhibitor,compared with clopidogrel in healthy humans[J].Brit J Clin Pharmaco,2007,63(4):421-430.
[32] TIRNAKSIZ E,PAMUKCU B,OFLAZ H,et al.Effect of high dose statin therapy on platelet function; statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease[J].J Thromb Thrombolys,2009,27(1):24-28. |
